



## **B-CLEAR<sup>®</sup>**

### **An Exclusive Sandwich-Cultured Hepatocyte System for Hepatobiliary Disposition US Patent 6,780,580, European Patent 1163517, and others issued & pending**

#### **Relevant References**

- Gefroh et al. 2007. "The Effect of Albumin on the Hepatobiliary Disposition of Taurocholate in B-CLEAR<sup>®</sup>-RT." Poster, AAPS Transporter Workshop 2007, North Bethesda, Maryland.
- Ghibellini et al. 2007. "In Vitro-In Vivo Correlation of Hepatobiliary Drug Clearance in Humans." *Clin Pharmacol Ther.* 2007 Jan 18; [Epub ahead of print]
- Ghibellini et al. 2007. "In Vitro and In Vivo Determination of Piperacillin Metabolism in Humans." *Drug Metab Dispos.* 35(3):345-349.
- Ansele et al. 2006. "The Expression and Function of the Copper Transporter, ATP7B, in B-CLEAR<sup>®</sup> and its Application as a Model for Assessing Drug-Induced Copper Toxicity." Poster, 14th North American ISSX Meeting, 2006, Rio Grande, Puerto Rico.
- Ansele et al. 2006. "Transport of Naloxone Glucuronide in B-CLEAR<sup>®</sup> and its Application as an In Vitro Model for Determining the Directional Transport of Metabolites." Poster, 14th North American ISSX Meeting, 2006, Rio Grande, Puerto Rico.
- Ghibellini et al. 2006. "Determination of the biliary excretion of piperacillin in humans using a novel method." *Br J Clin Pharmacol.* 62(3):304-8.
- Ghibellini et al. 2006. "Methods to evaluate biliary excretion of drugs in humans: an updated review." *Mol Pharm.* 3(3):198-211.
- McRae et al. "Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile Acid transport in human and rat hepatocytes." *J Pharmacol Exp Ther.* 318(3):1068-75.
- Turncliff et al. 2006. "Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes." *J Pharmacol Exp Ther.* 318(2):881-9.
- Zamek-Gliszczyński et al. 2006. "Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites." *Eur J Pharm Sci.* 27(5):447-86.
- Nezasa et al. 2006. "Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice." *Drug Metab Dispos.* 34(4):718-23.
- Turncliff et al. 2006. "Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes." *Biochem Pharmacol.* 71(10):1520-9. Tian et al. 2005. "Knocking down transport: applications of RNA interference in the study of drug transport proteins." *Drug Metab Rev.* 2005;37(4):705-23.
- Zhang et al. 2005. "Interspecies Variability of Transport Protein Functions in Sandwich-Cultured Rat, Dog, Monkey and Human Hepatocytes (B-CLEAR<sup>®</sup>)." Poster, 13th North American ISSX Meeting, 2005, Maui, Hawaii.
- Zhang et al. 2005. "Optimization of Transporter Expression and Function in Sandwich-Cultured Human Hepatocytes (B-CLEAR<sup>®</sup>-HU)." Poster, 13th North American ISSX Meeting, 2005, Maui, Hawaii.



- Hoffmaster et al. 2005. "Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid Peptide [d-penicillamine<sub>2,5</sub>]enkephalin." *Drug Metab Dispos.* 33(2):287-93.
- Kemp et al. 2005. "Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes." *Tox. Sci.* 83(2):207-214.
- Annaert & Brouwer. 2005. "Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes." *Drug Metab Dispos.* 33(3): 388-394.
- Zhang et al. 2005. "Role of glycosylation in trafficking of Mrp2 in sandwich-cultured rat hepatocytes." *Mol Pharmacol.* 67(4):1334-41.
- Chandra et al. 2005. "Short-term regulation of multidrug resistance-associated protein 3 in rat and human hepatocytes." *Am J Physiol Gastrointest Liver Physiol.* 288(6):G1252-8.
- Zamek-Gliszczynski et al. 2005. "Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of mrp2 and bcrp1." *Drug Metab Dispos.* 33(8):1158-65.
- Chandra et al. 2005. "Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver." *Drug Metab Dispos.* 33(8):1238-43.
- Chandra & Brouwer. 2004. "The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts." *Pharm. Res.* 21(5):719-735.
- Hoffmaster et al. 2004. "P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepatocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide." *Pharm. Res.* 21(7):1294-1302.
- Tian et al. 2004. "Modulation of Rat MRP2 Expression and Function in Sandwich-Cultured Rat Hepatocytes (SCRH) with Small Interfering RNA. Poster, 7th International ISSX Meeting, 2004, Vancouver, Canada.
- Dasgupta et al. 2004. "Estimation of Biliary Excretion using Sandwich-Cultured Rat Hepatocytes (B-CLEAR(TM)-RT)." Poster, 7th International ISSX Meeting, 2004, Vancouver, Canada.
- McRae et al. 2004. "Effects Of Ritonavir (Rtv) And Nevirapine (Nvp) On Hepatic Transport And The Biliary Excretion Index (Bei) Of Taurocholate (Tc) In Both Sandwich-Cultured Human And Rat Hepatocytes (Schh, Scrh)." Poster, 7th International ISSX Meeting, 2004, Vancouver, Canada.
- Ghibellini et al. 2004. "A novel method for the determination of biliary clearance in humans." *AAPS Journal.* 6(4):33-40.
- Kemp & Brouwer. 2004. "Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure." *Toxicol In Vitro.* 18(6):869-77.
- Tian et al. 2004. "Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes." *Mol Pharmacol.* 66(4):1004-10.
- Hoffmaster et al. 2004. "Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen<sub>2</sub>, D-Pen<sub>5</sub>]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems." *JPET* 311(3):1203-10.
- Zamek-Gliszczynski et al. 2003. "Pharmacokinetics of 5 (and 6)-Carboxy-2',7'-Dichlorofluorescein and Its Diacetate Promoiety in the Liver." *JPET.* 304:801-809.



- Zhang et al. 2003. "Nucleoside Transport in Primary Rat Hepatocytes Cultured in a Collagen-Sandwich Configuration." Poster, AAPS Annual Meeting and Exposition, 2003, Salt Lake City, Utah.
- Zhang et al. 2003. "UDP-Glucouronosyltransferase (UGT) Activity in Sandwich-Cultured Rat Hepatocytes." Poster, 12th North American ISSX Meeting, 2003, Providence, Rhode Island.
- Chandra et al. 2001. "Optimization of Culture Conditions for Determining Hepatobiliary Disposition of Taurocholate in Sandwich-Cultured Rat Hepatocytes." *In Vitro Cell. Dev. Biol. Anim.* (37):380-385.
- Annaert et al. 2001. "P-Glycoprotein-Mediated in vitro Biliary Excretion in Sandwich-Cultured Rat Hepatocytes." *Drug Metabol. Dispos.* 29(10):1277-1283.
- Zhang et al 2001. "Time Course of Multidrug Resistance-Associated Protein (MRP) 2 Expression, Localization, and Function in Sandwich-Cultured Rate Hepatocytes." Poster, AAPS Annual Meeting and Exposition, 2001, Denver, Colorado.
- Liu et al. 1999. "Biliary Excretion in Primary Rat Hepatocytes Cultured in a Collagen-Sandwich Configuration." *Am. J. Physiol.* 277(Gastro-intest. Liver Physiol. 40):G12-21.
- Liu et al. 1999. "Use of Ca<sup>2+</sup> Modulation to Evaluate Biliary Excretion in Sandwich-Cultured Rat Hepatocytes." *JPET.* 289(3):1592-1599.
- Liu et al. 1999. "Correlation of Biliary Excretion in Sandwich-Cultured Rate Hepatocytes and In Vivo in Rats." *Drug Metabol. Dispos.* 27(6):637-644.

### **About Qualyst, Inc.**

Qualyst was founded on breakthrough discoveries from research by three professors in the School of Pharmacy at the University of North Carolina at Chapel Hill. For many years, Qualyst's founders have pursued basic research to understand the fundamental principles behind absorption, distribution, metabolism and excretion processes at the cellular and molecular level, and to relate these processes to drug toxicity. Qualyst's mission is to develop and deliver these and other novel ADMET technologies to the life sciences industry that increase the efficiency and effectiveness of drug discovery and development.

### **Contact**

**QUALYST, INC.**

[www.qualyst.com](http://www.qualyst.com)

5410 Trinity Road, Suite 108  
Raleigh, NC 27607

919-313-6500 phone  
919-313-0163 fax  
[sales@qualyst.com](mailto:sales@qualyst.com)